KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Amortization of Deferred Charges (2016 - 2021)

Jazz Pharmaceuticals (JAZZ) has 11 years of Amortization of Deferred Charges data on record, last reported at $15.7 million in Q1 2021.

  • For Q1 2021, Amortization of Deferred Charges rose 30.73% year-over-year to $15.7 million; the TTM value through Mar 2021 reached $60.3 million, up 27.68%, while the annual FY2020 figure was $56.7 million, 22.12% up from the prior year.
  • Amortization of Deferred Charges reached $15.7 million in Q1 2021 per JAZZ's latest filing, down from $16.0 million in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $16.0 million in Q4 2020 and bottomed at $5.6 million in Q1 2017.
  • Average Amortization of Deferred Charges over 5 years is $11.3 million, with a median of $11.3 million recorded in 2018.
  • The widest YoY moves for Amortization of Deferred Charges: up 89.08% in 2018, down 4.62% in 2018.
  • A 5-year view of Amortization of Deferred Charges shows it stood at $10.8 million in 2017, then rose by 4.62% to $11.3 million in 2018, then increased by 6.11% to $12.0 million in 2019, then soared by 33.93% to $16.0 million in 2020, then dropped by 2.23% to $15.7 million in 2021.
  • Per Business Quant database, its latest 3 readings for Amortization of Deferred Charges were $15.7 million in Q1 2021, $16.0 million in Q4 2020, and $15.8 million in Q3 2020.